Reclaiming Life with Hemophilia: A Weekly Routine for Lasting Confidence
(BPT) - (4media group) - Article is sponsored and developed by Sanofi. Chayse, Harrison and Ashley were compensated by Sanofi.
Approximately 25,000 people living in the US with hemophilia A, a rare blood disorder, may share a diagnosis, but their experiences can vary based on unmet needs and treatment challenges.1,2 Hemophilia A causes a person's blood to not clot properly, which can result in spontaneous bleeding, joint damage, and chronic pain.1 Hemophilia requires lifelong disease management, so treatment goals may evolve over time.1,2 For Chayse and Harrison, changing to the number one most switched to factor VIII replacement for hemophilia A helped them achieve their goals.*
*Based on specialty pharmacy channel and HTC-reported data from October 2023 to May 2025.
Chayse: Easing the Treatment Burden
Diagnosed during his childhood, Chayse used the same factor treatment for over two decades. At seven years old, he learned to self-infuse at a hemophilia day camp, which gave him the confidence to explore his passion for music.
Passion turned profession, Chayse realized his treatment schedule was becoming a burden on his life as a musician. In total, he infused himself over 5,000 times - 180 times a year on average, which led him to consider a new treatment plan that offered a simpler routine without compromising bleed protection.
Chayse met with a Community Resource and Education Manager at Sanofi and learned about ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl], an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A.3 Chayse was excited about the prospect of a once-weekly treatment that keeps factor VIII activity levels near normal (> 40%) for multiple days of the week.3 After speaking to his doctor, they decided ALTUVIIIO would be a great fit and Chayse made the switch.
"When I realized what that infusion schedule could mean for my daily life, and my veins, I knew I wanted to try ALTUVIIIO," Chayse said.
Since starting on ALTUVIIIO in January 2024, Chayse's treatment burdens have eased. He doesn't need to infuse himself as often, and he no longer has to worry about transporting and packing as many doses of factor while traveling between treatments. Today, he has more time to focus on performing, teaching music, playing golf, or watching movies with his wife, Katie.
In a clinical study of adults and adolescents with hemophilia A, ALTUVIIIO prophylaxis resulted in 0.7 mean bleeds per year.†,‡
"Using ALTUVIIIO has simplified my routine, and the peace of mind knowing that I'm covered for longer has made me so happy," Chayse emphasized.
†Based on treated bleeds.
‡159 adults and adolescents with severe hemophilia (aged 12 years and older) were enrolled in the XTEND-1 study; 133 people were in Group 1 and switched to ALTUVIIIO prophylaxis from prior prophylaxis therapy. Efficacy of prophylaxis was evaluated in 128 of these patients.
Harrison and Ashley: Switching Therapies to Live a Fulfilled Childhood
When Ashley was pregnant with Harrison, she knew there was a high possibility of her son having hemophilia A as it runs in her family. A mom of three boys, two of them, including now five-year-old Harrison, are diagnosed with severe hemophilia A.
At the time, Harrison was treated with non-factor prophylaxis three times a week and supplemented with factor for breakthrough bleeds. Considering new options, Ashley wanted to ensure his treatment provided stable bleed protection without compromising his childhood.
"We wanted to limit how frequently he was getting hurt without stopping him from being the funny, sweet kid who loves to sing and play T-ball," Ashley said.
Ashley was at a conference where she listened in on a presentation on ALTUVIIIO. Interested to learn more, Ashley and Harrison spoke to his hematologist about the treatment and decided to try it for her son.
Since starting on ALTUVIIIO in 2023, Harrison has not experienced any breakthrough bleeding all while having a more efficient treatment schedule, allowing him to enjoy his favorite activities.
In a clinical study of children under 12 years of age with hemophilia A, ALTUVIIIO prophylaxis resulted in 0.6 mean bleeds per year.†,§
"Switching was worth it. We don't worry about supplementing with factor like we used to," Ashley said.
†Based on treated bleeds.
§ALTUVIIIO was studied in the XTEND-Kids study. The primary goal of the study was to determine whether or not children under 12 years of age developed inhibitors to ALTUVIIIO. 0 inhibitors were detected. Efficacy of prophylaxis was evaluated in 72 of these patients.
Starting a New Chapter with ALTUVIIIO
Before starting ALTUVIIIO, their doctors helped them understand the benefits of switching to ALTUVIIIO and its most common side effects, including headache and joint pain.3 Since switching, Chayse and Harrison have responded well to treatment, with effective bleed protection and higher-for-longer factor VIII levels. They feel peace of mind knowing their treatment schedules enable this level of bleed protection with once-weekly dosing.
"My hope is that I can encourage other people with hemophilia feel confident in taking some control over their own health. Finding a treatment plan that is the right fit for you is worth pursuing with your doctor," Chayse emphasized.
Patient experiences on ALTUVIIIO may vary, so talk to your doctor when making treatment decisions. To learn more, visit ALTUVIIIO.com.
INDICATION
ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).
Your healthcare provider may give you ALTUVIIIO when you have surgery.
IMPORTANT SAFETY INFORMATION
What is the most important information I need to know about ALTUVIIIO?
Do not attempt to give yourself an injection unless you have been taught how by your healthcare provider or hemophilia center. You must carefully follow your healthcare provider's instructions regarding the dose and schedule for injecting ALTUVIIIO so that your treatment will work best for you.
Who should not use ALTUVIIIO?
You should not use ALTUVIIIO if you have had an allergic reaction to it in the past.
What should I tell my healthcare provider before using ALTUVIIIO?
Tell your healthcare provider if you have had any medical problems, take any medications, including prescription and non-prescription medicines, supplements, or herbal medicines, are breastfeeding, or are pregnant or planning to become pregnant.
What are the possible side effects of ALTUVIIIO?
You can have an allergic reaction to ALTUVIIIO. Call your healthcare provider or emergency department right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.
Your body can also make antibodies called "inhibitors" against ALTUVIIIO. This can stop ALTUVIIIO from working properly. Your healthcare provider may give you blood tests to check for inhibitors.
The most common side effects of ALTUVIIIO are headache and joint pain.
These are not the only possible side effects of ALTUVIIIO. Tell your healthcare provider about any side effect that bothers you or does not go away.
Please see fullPrescribing Information.
Please consult your healthcare professional if you have any questions about your health or treatment.
References
- About Hemophilia. Centers for Disease Control and Prevention (CDC). Last reviewed March 5, 2025. Accessed June 13, 2025. https://www.cdc.gov/hemophilia/about/index.html
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158. doi:10.1111/hae.14046
- ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] prescribing information. Bioverativ Therapeutics, Inc. March 2025.
© 2025 Sanofi. All rights reserved. ALTUVIIIO and Sanofi are registered trademarks of Sanofi or an affiliate.
MAT-US-2505599-v1.0-07/2025
Source: BrandPoint
